Overview

Mifepristone as Adjunctive Therapy in Alzheimer's Disease

Status:
Terminated
Trial end date:
2005-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the effects of C-1073 (Mifepristone) on cognition in patients with Alzheimer's disease (AD) who are also taking an acetylcholinesterase inhibitor (Aricept, Exelon or Reminyl).
Phase:
Phase 2
Details
Lead Sponsor:
Corcept Therapeutics
Collaborator:
Institute for the Study of Aging (ISOA)
Treatments:
Mifepristone